A prototype biomarker that recognises antibiotic-induced gut dysbiosis has been created by a team from Ferring Pharmaceuticals, who believe the tool could help in developing future biotherapeutics.
Ferring Pharmaceuticals, Rebiotix and MyBiotics Pharma are to enter a research collaboration that focuses on live microbiota-based biotherapeutics to address bacterial vaginosis (BV).